American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: http://www.sciepub.com/journal/ajmcr Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
American Journal of Medical Case Reports. 2022, 10(7), 181-184
DOI: 10.12691/ajmcr-10-7-5
Open AccessCase Report

Cytogenetic Remission in Response to Dasatinib Monotherapy in Mixed-phenotype Acute Leukemia with t(9;22)(q34.1;q11.2) Translocation

Motoharu Shibusawa1,

1IMS group, Shinmatsudo Central General Hospital, Department of Hematology, Chiba, Japan

Pub. Date: August 03, 2022

Cite this paper:
Motoharu Shibusawa. Cytogenetic Remission in Response to Dasatinib Monotherapy in Mixed-phenotype Acute Leukemia with t(9;22)(q34.1;q11.2) Translocation. American Journal of Medical Case Reports. 2022; 10(7):181-184. doi: 10.12691/ajmcr-10-7-5

Abstract

The case of a 44-year-old Japanese woman diagnosed with mixed-phenotype acute leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 (MPAL-BA) is reported. Her white blood cell count was 5,100/μL with 13.0% blasts; positive for CD34, HLA-DR, MPO, CD33, CD19, cytoplasmic (cy) CD79a, CD22, CD10, and TdT; and negative for cyCD3. G-band cytogenetic analysis detected a normal karyotype. Fluorescence in situ hybridization detected BCR-ABL1 (9.0%) and a minor BCR-ABL1 mRNA at 4.2 × 104 copies/µg RNA. The patient was treated with dasatinib monotherapy (140 mg daily). Bone marrow examination revealed cytogenetic remission (CyCR) with minor BCR-ABL1 mRNA detected at 1.1 × 103 copies /µg RNA on day 31. No adverse events of dasatinib therapy were observed. MPAL-BA is very rare and dasatinib monotherapy efficacy for this diagnosis was previously unknown. The patient achieved CyCR with dasatinib monotherapy as first-line treatment. The present case suggests that dasatinib monotherapy may be effective and safe for MPAL-BA induction therapy.

Keywords:
mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2) BCR-ABL1 translocation mixed phenotype acute leukemia BCR-ABL1 dasatinib

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Borwitz, M.J., Bene, M.-C., Harris, N.L., Porwit, A., Matutes, E. and Arber, D. A., Acute leukaemias of ambiguous lineage, in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer, Lyon, 2017, 180-187.
 
[2]  Porwit, Anna and Béné, Marie C., “Acute Leukemias of Ambiguous Origin”. American Journal of Clinical Pathology, 144(3). 361-376, 2015.
 
[3]  Matutes, Estella, Pickl, Winfried F., Van'T Veer, Mars, Morilla, Ricardo, Swansbury, John, Strobl, Herbert, Attarbaschi, Andishe, Hopfinger, Georg, Ashley, Sue, Bene, Marie Christine, Porwit, Anna, Orfao, Alberto, Lemez, Petr, Schabath, Richard and Ludwig, Wolf-Dieter, “Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification”. Blood, 117(11). 3163-3171, 2011.
 
[4]  Shimizu, H., Yokohama, A., Hatsumi, N., Takada, S., Handa, H., Sakura, T. and Nojima, Y., “Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era”. Eur J Haematol, 93(4). 297-301, Oct 2014.
 
[5]  Kawajiri, C., Tanaka, H., Hashimoto, S., Takeda, Y., Sakai, S., Takagi, T., Takeuchi, M., Ohwada, C., Sakaida, E., Shimizu, N. and Nakaseko, C., “Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status”. Int J Hematol, 99(4). 513-8, Apr 2014.
 
[6]  Takata, Hiroyuki, Ikebe, Taichi, Sasaki, Hitohiro, Miyazaki, Yasuhiko, Ohtsuka, Eiichi, Saburi, Yoshio, Ogata, Masao and Shirao, Kuniaki, “Two Elderly Patients with Philadelphia Chromosome Positive Mixed Phenotype Acute Leukemia Who Were Successfully Treated with Dasatinib and Prednisolone”. Internal Medicine, 55(9). 1177-1181, 2016.
 
[7]  Ravandi, F., O'Brien, S., Thomas, D., Faderl, S., Jones, D., Garris, R., Dara, S., Jorgensen, J., Kebriaei, P., Champlin, R., Borthakur, G., Burger, J., Ferrajoli, A., Garcia-Manero, G., Wierda, W., Cortes, J. and Kantarjian, H., “First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia”. Blood, 116(12). 2070-7, Sep 23 2010.
 
[8]  Lindauer, M. and Hochhaus, A., “Dasatinib”. Recent Results Cancer Res, 212. 29-68, 2018.